The specialty drug pipeline is evolving and contributing to rising costs. Over the last 10 years, the total specialty-drug market spend has approximately doubled, and is expected to hit $310 billion this year. 

The staggering specialty market increase is due in part to two major shifts. First, the market has historically been impacted by less than 2% of the population with relatively rare diseases using specialty prescriptions. However, rare diseases impact 30 million people in the U.S. Specialty drug utilization has also moved beyond rare diseases to now target more common, chronic conditions, opening the door for more people to use these prescriptions.

Second, nearly 80% of the drugs that the FDA is expected to approve in 2023 are specialty drugs. The cost of specialty drugs has also increased due to high demand, greater availability, and laborious manufacturing and handling. Manufacturers are increasingly focused on specialty because these drugs are more profitable to make due to the high markup potential and lack of competition. Therefore, they have become more frequently prescribed and yet less affordable.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events
  • Access to other award-winning ALM websites including and

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.